Review



antibody against p p65  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc antibody against p p65
    Narciclasine-mediated H3K18la is associated with the activation of the NF-κB pathway in ECs . ( A ) Schematic diagram of histone H3 lysine-18 lactylation (H3K18la) inhibition. ( B - D ) Western blotting analysis of VCAM1 (110 kDa), ICAM1 (90 kDa), and H3K18la (15 kDa) in HUVECs under the following conditions: ( B ) Stimulation with ox-LDL (100 µg/mL) in the presence or absence of 2-deoxy-D-glucose (2-DG, 0.5 mM), or sodium lactate (NaLac, 10 mM) for 24 h; ( C ) Transfection with negative control siRNA (siNC), siLDHA, or siP300 for 48 h, followed by stimulation with ox-LDL (100 µg/mL) for 24 h; ( D ) Stimulation with ox-LDL (100 µg/mL) in the presence or absence of dichloroacetate (DCA, 10 mM) for 24 h. Protein band intensities were quantified using ImageJ (version 1.48); H3K18la was normalized to H3 (15 kDa), and VCAM1 and ICAM1 to β-actin (42 kDa). Quantitative data are shown in Supplementary Fig. S14B-D ( n = 3 biological replicates). ( E ) Schematic diagram of H3K18la promotion. ( F - G ) Western blotting analysis of VCAM1 and H3K18la in HUVECs under the following conditions: ( F ) Pretreatment with or without narciclasine (Narc, 20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in combination with either NaLac (10 mM) or sodium acetate (NaAc, 10 mM) for 24 h; ( G ) Pretreatment with or without Narc (20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in the presence or absence of entinostat (MS275, 0.5 µM) for 24 h. Protein band intensities were quantified using ImageJ, with H3K18la was normalized to H3, VCAM1 to β-actin. Quantitative data are shown in Supplementary Fig. S14E and F ( n = 3 biological replicates). ( H - I ) HUVECs were pretreated with or without 20 nM Narc for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in the presence or absence of 10 mM NaLac for 24 h. ( H ) Representative images of PKH26-labeled THP-1 monocyte adhesion to endothelial cells (scale bar = 250 μm, 10× magnification). The right panel shows the quantification of adherent monocytes from 10 random fields per replicate, expressed as cells per field ( n = 3 biological replicates). ( I ) Representative images of RAW 264.7 macrophage chemotaxis toward HUVEC-conditioned medium (Scale bar = 50 μm, 20× magnification). The right panel shows the quantification of migrated cells from 5 random fields per well, expressed as cells per field ( n = 3 biological replicates). ( J ) Western blotting analysis of <t>p-p65</t> (65 kDa), and p65 (65 kDa) in HUVECs pretreated with or without Narc (20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in combination with either NaLac (10 mM) or MS275 (0.5 µM) for 1 h. Protein band intensities were quantified using ImageJ, with the p-p65/p65 ratio (right panel) calculated after normalizing both p-p65 and total p65 to β-actin ( n = 3 biological replicates). ( K ) Genome browser tracks of CUT&Tag signals for H3K18la at representative target gene loci in HUVECs. The tracks display normalized signal intensity (Reads Per Kilobase per Million mapped reads, RPKM) from a single biological replicate, aligned to the GRCh38/hg38 genome build. ( L ) KEGG pathway analysis of the 1147 genes overlapping between H3K18la-bound genes and genes downregulated by Narc. The Narc-downregulated gene set was defined from RNA-seq data (FDR < 0.05, |fold change| > 1.5; n = 3 biological replicates). The underlying RNA-seq data are available under GEO accession GSE202556 . ( M ) ChIP-qPCR analyses of H3K18la enrichment at the promoters of the indicated genes in HUVECs treated with ox-LDL (100 µg/mL, 24 h) in the presence or absence of Narc (20 nM). Data were normalized to input chromatin and are presented as fold enrichment relative to the IgG control ( n = 4 biological replicates). All data were represented as mean ± SD. Statistical analysis was performed by one-way ANOVA followed by Tukey’s multiple comparisons test
    Antibody Against P P65, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 2211 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3031/Phospho-NF-kappaB+p65+(Ser536)+Antibody/pmc12876478-75-0-8
    Average 96 stars, based on 2211 article reviews
    antibody against p p65 - by Bioz Stars, 2026-10
    96/100 stars

    Images

    1) Product Images from "Narciclasine Alleviates Endothelial Inflammation and Atherosclerosis Initiation by Inhibiting Histone Lactylation-Mediated NF-κB Activation"

    Article Title: Narciclasine Alleviates Endothelial Inflammation and Atherosclerosis Initiation by Inhibiting Histone Lactylation-Mediated NF-κB Activation

    Journal: Inflammation

    doi: 10.1007/s10753-025-02446-7

    Narciclasine-mediated H3K18la is associated with the activation of the NF-κB pathway in ECs . ( A ) Schematic diagram of histone H3 lysine-18 lactylation (H3K18la) inhibition. ( B - D ) Western blotting analysis of VCAM1 (110 kDa), ICAM1 (90 kDa), and H3K18la (15 kDa) in HUVECs under the following conditions: ( B ) Stimulation with ox-LDL (100 µg/mL) in the presence or absence of 2-deoxy-D-glucose (2-DG, 0.5 mM), or sodium lactate (NaLac, 10 mM) for 24 h; ( C ) Transfection with negative control siRNA (siNC), siLDHA, or siP300 for 48 h, followed by stimulation with ox-LDL (100 µg/mL) for 24 h; ( D ) Stimulation with ox-LDL (100 µg/mL) in the presence or absence of dichloroacetate (DCA, 10 mM) for 24 h. Protein band intensities were quantified using ImageJ (version 1.48); H3K18la was normalized to H3 (15 kDa), and VCAM1 and ICAM1 to β-actin (42 kDa). Quantitative data are shown in Supplementary Fig. S14B-D ( n = 3 biological replicates). ( E ) Schematic diagram of H3K18la promotion. ( F - G ) Western blotting analysis of VCAM1 and H3K18la in HUVECs under the following conditions: ( F ) Pretreatment with or without narciclasine (Narc, 20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in combination with either NaLac (10 mM) or sodium acetate (NaAc, 10 mM) for 24 h; ( G ) Pretreatment with or without Narc (20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in the presence or absence of entinostat (MS275, 0.5 µM) for 24 h. Protein band intensities were quantified using ImageJ, with H3K18la was normalized to H3, VCAM1 to β-actin. Quantitative data are shown in Supplementary Fig. S14E and F ( n = 3 biological replicates). ( H - I ) HUVECs were pretreated with or without 20 nM Narc for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in the presence or absence of 10 mM NaLac for 24 h. ( H ) Representative images of PKH26-labeled THP-1 monocyte adhesion to endothelial cells (scale bar = 250 μm, 10× magnification). The right panel shows the quantification of adherent monocytes from 10 random fields per replicate, expressed as cells per field ( n = 3 biological replicates). ( I ) Representative images of RAW 264.7 macrophage chemotaxis toward HUVEC-conditioned medium (Scale bar = 50 μm, 20× magnification). The right panel shows the quantification of migrated cells from 5 random fields per well, expressed as cells per field ( n = 3 biological replicates). ( J ) Western blotting analysis of p-p65 (65 kDa), and p65 (65 kDa) in HUVECs pretreated with or without Narc (20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in combination with either NaLac (10 mM) or MS275 (0.5 µM) for 1 h. Protein band intensities were quantified using ImageJ, with the p-p65/p65 ratio (right panel) calculated after normalizing both p-p65 and total p65 to β-actin ( n = 3 biological replicates). ( K ) Genome browser tracks of CUT&Tag signals for H3K18la at representative target gene loci in HUVECs. The tracks display normalized signal intensity (Reads Per Kilobase per Million mapped reads, RPKM) from a single biological replicate, aligned to the GRCh38/hg38 genome build. ( L ) KEGG pathway analysis of the 1147 genes overlapping between H3K18la-bound genes and genes downregulated by Narc. The Narc-downregulated gene set was defined from RNA-seq data (FDR < 0.05, |fold change| > 1.5; n = 3 biological replicates). The underlying RNA-seq data are available under GEO accession GSE202556 . ( M ) ChIP-qPCR analyses of H3K18la enrichment at the promoters of the indicated genes in HUVECs treated with ox-LDL (100 µg/mL, 24 h) in the presence or absence of Narc (20 nM). Data were normalized to input chromatin and are presented as fold enrichment relative to the IgG control ( n = 4 biological replicates). All data were represented as mean ± SD. Statistical analysis was performed by one-way ANOVA followed by Tukey’s multiple comparisons test
    Figure Legend Snippet: Narciclasine-mediated H3K18la is associated with the activation of the NF-κB pathway in ECs . ( A ) Schematic diagram of histone H3 lysine-18 lactylation (H3K18la) inhibition. ( B - D ) Western blotting analysis of VCAM1 (110 kDa), ICAM1 (90 kDa), and H3K18la (15 kDa) in HUVECs under the following conditions: ( B ) Stimulation with ox-LDL (100 µg/mL) in the presence or absence of 2-deoxy-D-glucose (2-DG, 0.5 mM), or sodium lactate (NaLac, 10 mM) for 24 h; ( C ) Transfection with negative control siRNA (siNC), siLDHA, or siP300 for 48 h, followed by stimulation with ox-LDL (100 µg/mL) for 24 h; ( D ) Stimulation with ox-LDL (100 µg/mL) in the presence or absence of dichloroacetate (DCA, 10 mM) for 24 h. Protein band intensities were quantified using ImageJ (version 1.48); H3K18la was normalized to H3 (15 kDa), and VCAM1 and ICAM1 to β-actin (42 kDa). Quantitative data are shown in Supplementary Fig. S14B-D ( n = 3 biological replicates). ( E ) Schematic diagram of H3K18la promotion. ( F - G ) Western blotting analysis of VCAM1 and H3K18la in HUVECs under the following conditions: ( F ) Pretreatment with or without narciclasine (Narc, 20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in combination with either NaLac (10 mM) or sodium acetate (NaAc, 10 mM) for 24 h; ( G ) Pretreatment with or without Narc (20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in the presence or absence of entinostat (MS275, 0.5 µM) for 24 h. Protein band intensities were quantified using ImageJ, with H3K18la was normalized to H3, VCAM1 to β-actin. Quantitative data are shown in Supplementary Fig. S14E and F ( n = 3 biological replicates). ( H - I ) HUVECs were pretreated with or without 20 nM Narc for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in the presence or absence of 10 mM NaLac for 24 h. ( H ) Representative images of PKH26-labeled THP-1 monocyte adhesion to endothelial cells (scale bar = 250 μm, 10× magnification). The right panel shows the quantification of adherent monocytes from 10 random fields per replicate, expressed as cells per field ( n = 3 biological replicates). ( I ) Representative images of RAW 264.7 macrophage chemotaxis toward HUVEC-conditioned medium (Scale bar = 50 μm, 20× magnification). The right panel shows the quantification of migrated cells from 5 random fields per well, expressed as cells per field ( n = 3 biological replicates). ( J ) Western blotting analysis of p-p65 (65 kDa), and p65 (65 kDa) in HUVECs pretreated with or without Narc (20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in combination with either NaLac (10 mM) or MS275 (0.5 µM) for 1 h. Protein band intensities were quantified using ImageJ, with the p-p65/p65 ratio (right panel) calculated after normalizing both p-p65 and total p65 to β-actin ( n = 3 biological replicates). ( K ) Genome browser tracks of CUT&Tag signals for H3K18la at representative target gene loci in HUVECs. The tracks display normalized signal intensity (Reads Per Kilobase per Million mapped reads, RPKM) from a single biological replicate, aligned to the GRCh38/hg38 genome build. ( L ) KEGG pathway analysis of the 1147 genes overlapping between H3K18la-bound genes and genes downregulated by Narc. The Narc-downregulated gene set was defined from RNA-seq data (FDR < 0.05, |fold change| > 1.5; n = 3 biological replicates). The underlying RNA-seq data are available under GEO accession GSE202556 . ( M ) ChIP-qPCR analyses of H3K18la enrichment at the promoters of the indicated genes in HUVECs treated with ox-LDL (100 µg/mL, 24 h) in the presence or absence of Narc (20 nM). Data were normalized to input chromatin and are presented as fold enrichment relative to the IgG control ( n = 4 biological replicates). All data were represented as mean ± SD. Statistical analysis was performed by one-way ANOVA followed by Tukey’s multiple comparisons test

    Techniques Used: Activation Assay, Inhibition, Western Blot, Transfection, Negative Control, Labeling, Chemotaxis Assay, RNA Sequencing, ChIP-qPCR, Control

    Related Articles

    Incubation:

    Article Title: Xaliproden improves diabetic kidney disease through JNK-mediated renal tubular protection
    Article Snippet: Diabetic kidney disease (DKD) is a major diabetic complication and the primary global cause of end-stage renal disease.. Hyperglycemia triggers multiple pathological signaling pathways and ultimately leads to structural alterations and functional decline in the kidney.. Xaliproden is a 5-HT1A receptor agonist originally developed for its neuroprotective effects; however, its impacts on renal disease remain unknown.

    Article Title: Yinhuo Decoction attenuates depression-like behaviors and promotes M2 microglia polarization by regulating PI3K/Akt/NF-κB signaling pathway in a murine model of menopausal depression.
    Article Snippet: Ethnopharmacological relevance: Yinhuo Decoction (YHD), a classical Chinese herbal formula for yin-nourishing and kidney-tonifying, has been traditionally prescribed for depression and female climacteric syndrome, and shows therapeutic potential for menopausal depression (MD).. While modern pharmacological studies confirm its potent anti-inflammatory properties, the role of YHD in regulating microglial polarization and its key active components remains unclear.. Aim of the study: This study aimed to identify the key active components and molecular targets of YHD responsible for anti-neuroinflammation and to elucidate its underlying mechanisms.

    Article Title: Fumarate loss destabilizes mitochondria and activates cGAS-STING in OLP.
    Article Snippet: .. The membrane was blocked with 5% skim milk and incubated with primary antibodies TFAM (22586–1-AP, proteintech, America), cGAS (26416–1-AP, proteintech, America), STING (ab181125, abcam, UK), TBK1(3504S, CST, America), p-TBK1 (5483s, CST, America), P65 (8242S, CST, America), p-P65 (3031S, CST, America), IRF3 (4302S, CST, America), p-IRF3 (4947S, CST, America), Actin (A5441, sigma, America) overnight at 4◦C, then with HRP-conjugated secondary antibodies (Goat Anti-Mouse/Rabbit IgG(H+L)-HRP, A0216/A0208, Beyotime, China) for 1 h. Signals were detected using an ECL kit and a fluorescence chemiluminescence imaging system. ..

    Membrane:

    Article Title: Atomoxetine suppresses nitric oxide synthesis induced by lipopolysaccharide in BV-2 microglia cells through the modulation of STAT1 and STAT3.
    Article Snippet: Atomoxetine (ATX), a selective noradrenaline reuptake inhibitor that is widely used to treat attention-deficit hyperactivity disorder, has recently been suggested to exert neuroprotective effects by modulating inflammatory responses in the central nervous system, particularly in microglial cells.. In this study, we investigated the effect of ATX on BV-2 microglial cells.. Upon administration of 50 μM ATX, a significant suppression of lipopolysaccharide (LPS)-induced nitric oxide (NO) production was observed.

    Article Title: Fumarate loss destabilizes mitochondria and activates cGAS-STING in OLP.
    Article Snippet: .. The membrane was blocked with 5% skim milk and incubated with primary antibodies TFAM (22586–1-AP, proteintech, America), cGAS (26416–1-AP, proteintech, America), STING (ab181125, abcam, UK), TBK1(3504S, CST, America), p-TBK1 (5483s, CST, America), P65 (8242S, CST, America), p-P65 (3031S, CST, America), IRF3 (4302S, CST, America), p-IRF3 (4947S, CST, America), Actin (A5441, sigma, America) overnight at 4◦C, then with HRP-conjugated secondary antibodies (Goat Anti-Mouse/Rabbit IgG(H+L)-HRP, A0216/A0208, Beyotime, China) for 1 h. Signals were detected using an ECL kit and a fluorescence chemiluminescence imaging system. ..

    Western Blot:

    Article Title: Histone demethylase KDM4B epigenetically controls NLRP3 expression to enhance inflammatory responses
    Article Snippet: Anti-AIM2 (WB, 1:1000) , Cell Signaling Technology , 13095. .. Anti-p-p65 (WB, 1:1000) , Cell Signaling Technology , 3031S. .. Anti-p65 (WB, 1:1000) , Cell Signaling Technology , 8242S.

    Nucleic Acid Electrophoresis:

    Article Title: Yinhuo Decoction attenuates depression-like behaviors and promotes M2 microglia polarization by regulating PI3K/Akt/NF-κB signaling pathway in a murine model of menopausal depression.
    Article Snippet: Ethnopharmacological relevance: Yinhuo Decoction (YHD), a classical Chinese herbal formula for yin-nourishing and kidney-tonifying, has been traditionally prescribed for depression and female climacteric syndrome, and shows therapeutic potential for menopausal depression (MD).. While modern pharmacological studies confirm its potent anti-inflammatory properties, the role of YHD in regulating microglial polarization and its key active components remains unclear.. Aim of the study: This study aimed to identify the key active components and molecular targets of YHD responsible for anti-neuroinflammation and to elucidate its underlying mechanisms.

    Fluorescence:

    Article Title: Fumarate loss destabilizes mitochondria and activates cGAS-STING in OLP.
    Article Snippet: .. The membrane was blocked with 5% skim milk and incubated with primary antibodies TFAM (22586–1-AP, proteintech, America), cGAS (26416–1-AP, proteintech, America), STING (ab181125, abcam, UK), TBK1(3504S, CST, America), p-TBK1 (5483s, CST, America), P65 (8242S, CST, America), p-P65 (3031S, CST, America), IRF3 (4302S, CST, America), p-IRF3 (4947S, CST, America), Actin (A5441, sigma, America) overnight at 4◦C, then with HRP-conjugated secondary antibodies (Goat Anti-Mouse/Rabbit IgG(H+L)-HRP, A0216/A0208, Beyotime, China) for 1 h. Signals were detected using an ECL kit and a fluorescence chemiluminescence imaging system. ..

    Imaging:

    Article Title: Fumarate loss destabilizes mitochondria and activates cGAS-STING in OLP.
    Article Snippet: .. The membrane was blocked with 5% skim milk and incubated with primary antibodies TFAM (22586–1-AP, proteintech, America), cGAS (26416–1-AP, proteintech, America), STING (ab181125, abcam, UK), TBK1(3504S, CST, America), p-TBK1 (5483s, CST, America), P65 (8242S, CST, America), p-P65 (3031S, CST, America), IRF3 (4302S, CST, America), p-IRF3 (4947S, CST, America), Actin (A5441, sigma, America) overnight at 4◦C, then with HRP-conjugated secondary antibodies (Goat Anti-Mouse/Rabbit IgG(H+L)-HRP, A0216/A0208, Beyotime, China) for 1 h. Signals were detected using an ECL kit and a fluorescence chemiluminescence imaging system. ..



    Similar Products

    anti dsdna antibodies  (Chondrex Inc)
    94
    Chondrex Inc anti dsdna antibodies
    Anti Dsdna Antibodies, supplied by Chondrex Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3031/Mouse+Anti-dsDNA+IgG+Antibody+Assay+Kit/pm42015268-115-20-22
    Average 94 stars, based on 1 article reviews
    anti dsdna antibodies - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    phospho p65  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc phospho p65
    Phospho P65, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3031/Phospho-NF-kappaB+p65+(Ser536)+Antibody/pm41926748-90-8-11
    Average 96 stars, based on 1 article reviews
    phospho p65 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    p p65  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc p p65
    P P65, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3031/Phospho-NF-kappaB+p65+(Ser536)+Antibody/pm41775094-99-36-38
    Average 96 stars, based on 1 article reviews
    p p65 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    anti phospho nuclear factor kappa b  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc anti phospho nuclear factor kappa b
    Anti Phospho Nuclear Factor Kappa B, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3031/Phospho-NF-kappaB+p65+(Ser536)+Antibody/pm41759989-65-60-68
    Average 96 stars, based on 1 article reviews
    anti phospho nuclear factor kappa b - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    cell signaling rrid ab 331285  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc cell signaling rrid ab 331285
    Cell Signaling Rrid Ab 331285, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3031/Phospho-NF-kappaB+p65+(Ser536)+Antibody/pm41724286-174-54-54
    Average 96 stars, based on 1 article reviews
    cell signaling rrid ab 331285 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    3031s  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc 3031s
    3031s, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3031/Phospho-NF-kappaB+p65+(Ser536)+Antibody/pmc12987974-5-8-4
    Average 96 stars, based on 1 article reviews
    3031s - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    mouse  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc mouse
    Mouse, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3031/Phospho-NF-kappaB+p65+(Ser536)+Antibody/pm41651304-158-47-49
    Average 96 stars, based on 1 article reviews
    mouse - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    antibody against p p65  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc antibody against p p65
    Narciclasine-mediated H3K18la is associated with the activation of the NF-κB pathway in ECs . ( A ) Schematic diagram of histone H3 lysine-18 lactylation (H3K18la) inhibition. ( B - D ) Western blotting analysis of VCAM1 (110 kDa), ICAM1 (90 kDa), and H3K18la (15 kDa) in HUVECs under the following conditions: ( B ) Stimulation with ox-LDL (100 µg/mL) in the presence or absence of 2-deoxy-D-glucose (2-DG, 0.5 mM), or sodium lactate (NaLac, 10 mM) for 24 h; ( C ) Transfection with negative control siRNA (siNC), siLDHA, or siP300 for 48 h, followed by stimulation with ox-LDL (100 µg/mL) for 24 h; ( D ) Stimulation with ox-LDL (100 µg/mL) in the presence or absence of dichloroacetate (DCA, 10 mM) for 24 h. Protein band intensities were quantified using ImageJ (version 1.48); H3K18la was normalized to H3 (15 kDa), and VCAM1 and ICAM1 to β-actin (42 kDa). Quantitative data are shown in Supplementary Fig. S14B-D ( n = 3 biological replicates). ( E ) Schematic diagram of H3K18la promotion. ( F - G ) Western blotting analysis of VCAM1 and H3K18la in HUVECs under the following conditions: ( F ) Pretreatment with or without narciclasine (Narc, 20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in combination with either NaLac (10 mM) or sodium acetate (NaAc, 10 mM) for 24 h; ( G ) Pretreatment with or without Narc (20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in the presence or absence of entinostat (MS275, 0.5 µM) for 24 h. Protein band intensities were quantified using ImageJ, with H3K18la was normalized to H3, VCAM1 to β-actin. Quantitative data are shown in Supplementary Fig. S14E and F ( n = 3 biological replicates). ( H - I ) HUVECs were pretreated with or without 20 nM Narc for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in the presence or absence of 10 mM NaLac for 24 h. ( H ) Representative images of PKH26-labeled THP-1 monocyte adhesion to endothelial cells (scale bar = 250 μm, 10× magnification). The right panel shows the quantification of adherent monocytes from 10 random fields per replicate, expressed as cells per field ( n = 3 biological replicates). ( I ) Representative images of RAW 264.7 macrophage chemotaxis toward HUVEC-conditioned medium (Scale bar = 50 μm, 20× magnification). The right panel shows the quantification of migrated cells from 5 random fields per well, expressed as cells per field ( n = 3 biological replicates). ( J ) Western blotting analysis of <t>p-p65</t> (65 kDa), and p65 (65 kDa) in HUVECs pretreated with or without Narc (20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in combination with either NaLac (10 mM) or MS275 (0.5 µM) for 1 h. Protein band intensities were quantified using ImageJ, with the p-p65/p65 ratio (right panel) calculated after normalizing both p-p65 and total p65 to β-actin ( n = 3 biological replicates). ( K ) Genome browser tracks of CUT&Tag signals for H3K18la at representative target gene loci in HUVECs. The tracks display normalized signal intensity (Reads Per Kilobase per Million mapped reads, RPKM) from a single biological replicate, aligned to the GRCh38/hg38 genome build. ( L ) KEGG pathway analysis of the 1147 genes overlapping between H3K18la-bound genes and genes downregulated by Narc. The Narc-downregulated gene set was defined from RNA-seq data (FDR < 0.05, |fold change| > 1.5; n = 3 biological replicates). The underlying RNA-seq data are available under GEO accession GSE202556 . ( M ) ChIP-qPCR analyses of H3K18la enrichment at the promoters of the indicated genes in HUVECs treated with ox-LDL (100 µg/mL, 24 h) in the presence or absence of Narc (20 nM). Data were normalized to input chromatin and are presented as fold enrichment relative to the IgG control ( n = 4 biological replicates). All data were represented as mean ± SD. Statistical analysis was performed by one-way ANOVA followed by Tukey’s multiple comparisons test
    Antibody Against P P65, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3031/Phospho-NF-kappaB+p65+(Ser536)+Antibody/pmc12876478-75-0-8
    Average 96 stars, based on 1 article reviews
    antibody against p p65 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    phospho nuclear factor kappa b nf κb p65  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc phospho nuclear factor kappa b nf κb p65
    Cedrol inhibited toll-like receptor 4-mediated mitogen-activated protein kinase and nuclear factor <t>kappa</t> B signaling in vivo and in vitro . A-D: Phosphorylated and total protein abundance of mitogen-activated protein kinase signaling molecules [extracellular regulated protein kinase (ERK)1/2, c-Jun N-terminal kinase (JNK), p38] in colonic tissues of mice ( n = 6); E: Cellular viability was quantified with the cell counting kit-8 method ( n = 3); F-H: Proinflammatory cytokine expression in RAW264.7 macrophages across experimental groups ( n = 3); I-K: Inducible nitric oxide synthase and cyclooxygenase-2 protein expression in RAW264.7 cells across groups ( n = 3); L-P: Phosphorylated and total protein expression of ERK1/2, JNK, p38 and nuclear factor kappa B <t>p65</t> in RAW264.7 macrophages ( n = 3). Data are expressed as mean ± SD. a P < 0.05. b P < 0.01. c P < 0.001. d P < 0.0001. CE: Cedrol; DSS: Dextran sulfate sodium; ERK: Extracellular regulated protein kinase; p-ERK: Phospho-extracellular regulated protein kinase; JNK: C-Jun N-terminal kinase; p-JNK: Phospho-c-Jun N-terminal kinase; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; TNF: Tumor necrosis factor; IL: Interleukin; mRNA: Messenger RNA; LPS: Lipopolysaccharide; iNOS: Inducible nitric oxide synthase; COX-2: Cyclooxygenase-2.
    Phospho Nuclear Factor Kappa B Nf κb P65, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3031/Phospho-NF-kappaB+p65+(Ser536)+Antibody/pmc12809186-106-34-43
    Average 96 stars, based on 1 article reviews
    phospho nuclear factor kappa b nf κb p65 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Narciclasine-mediated H3K18la is associated with the activation of the NF-κB pathway in ECs . ( A ) Schematic diagram of histone H3 lysine-18 lactylation (H3K18la) inhibition. ( B - D ) Western blotting analysis of VCAM1 (110 kDa), ICAM1 (90 kDa), and H3K18la (15 kDa) in HUVECs under the following conditions: ( B ) Stimulation with ox-LDL (100 µg/mL) in the presence or absence of 2-deoxy-D-glucose (2-DG, 0.5 mM), or sodium lactate (NaLac, 10 mM) for 24 h; ( C ) Transfection with negative control siRNA (siNC), siLDHA, or siP300 for 48 h, followed by stimulation with ox-LDL (100 µg/mL) for 24 h; ( D ) Stimulation with ox-LDL (100 µg/mL) in the presence or absence of dichloroacetate (DCA, 10 mM) for 24 h. Protein band intensities were quantified using ImageJ (version 1.48); H3K18la was normalized to H3 (15 kDa), and VCAM1 and ICAM1 to β-actin (42 kDa). Quantitative data are shown in Supplementary Fig. S14B-D ( n = 3 biological replicates). ( E ) Schematic diagram of H3K18la promotion. ( F - G ) Western blotting analysis of VCAM1 and H3K18la in HUVECs under the following conditions: ( F ) Pretreatment with or without narciclasine (Narc, 20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in combination with either NaLac (10 mM) or sodium acetate (NaAc, 10 mM) for 24 h; ( G ) Pretreatment with or without Narc (20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in the presence or absence of entinostat (MS275, 0.5 µM) for 24 h. Protein band intensities were quantified using ImageJ, with H3K18la was normalized to H3, VCAM1 to β-actin. Quantitative data are shown in Supplementary Fig. S14E and F ( n = 3 biological replicates). ( H - I ) HUVECs were pretreated with or without 20 nM Narc for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in the presence or absence of 10 mM NaLac for 24 h. ( H ) Representative images of PKH26-labeled THP-1 monocyte adhesion to endothelial cells (scale bar = 250 μm, 10× magnification). The right panel shows the quantification of adherent monocytes from 10 random fields per replicate, expressed as cells per field ( n = 3 biological replicates). ( I ) Representative images of RAW 264.7 macrophage chemotaxis toward HUVEC-conditioned medium (Scale bar = 50 μm, 20× magnification). The right panel shows the quantification of migrated cells from 5 random fields per well, expressed as cells per field ( n = 3 biological replicates). ( J ) Western blotting analysis of p-p65 (65 kDa), and p65 (65 kDa) in HUVECs pretreated with or without Narc (20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in combination with either NaLac (10 mM) or MS275 (0.5 µM) for 1 h. Protein band intensities were quantified using ImageJ, with the p-p65/p65 ratio (right panel) calculated after normalizing both p-p65 and total p65 to β-actin ( n = 3 biological replicates). ( K ) Genome browser tracks of CUT&Tag signals for H3K18la at representative target gene loci in HUVECs. The tracks display normalized signal intensity (Reads Per Kilobase per Million mapped reads, RPKM) from a single biological replicate, aligned to the GRCh38/hg38 genome build. ( L ) KEGG pathway analysis of the 1147 genes overlapping between H3K18la-bound genes and genes downregulated by Narc. The Narc-downregulated gene set was defined from RNA-seq data (FDR < 0.05, |fold change| > 1.5; n = 3 biological replicates). The underlying RNA-seq data are available under GEO accession GSE202556 . ( M ) ChIP-qPCR analyses of H3K18la enrichment at the promoters of the indicated genes in HUVECs treated with ox-LDL (100 µg/mL, 24 h) in the presence or absence of Narc (20 nM). Data were normalized to input chromatin and are presented as fold enrichment relative to the IgG control ( n = 4 biological replicates). All data were represented as mean ± SD. Statistical analysis was performed by one-way ANOVA followed by Tukey’s multiple comparisons test

    Journal: Inflammation

    Article Title: Narciclasine Alleviates Endothelial Inflammation and Atherosclerosis Initiation by Inhibiting Histone Lactylation-Mediated NF-κB Activation

    doi: 10.1007/s10753-025-02446-7

    Figure Lengend Snippet: Narciclasine-mediated H3K18la is associated with the activation of the NF-κB pathway in ECs . ( A ) Schematic diagram of histone H3 lysine-18 lactylation (H3K18la) inhibition. ( B - D ) Western blotting analysis of VCAM1 (110 kDa), ICAM1 (90 kDa), and H3K18la (15 kDa) in HUVECs under the following conditions: ( B ) Stimulation with ox-LDL (100 µg/mL) in the presence or absence of 2-deoxy-D-glucose (2-DG, 0.5 mM), or sodium lactate (NaLac, 10 mM) for 24 h; ( C ) Transfection with negative control siRNA (siNC), siLDHA, or siP300 for 48 h, followed by stimulation with ox-LDL (100 µg/mL) for 24 h; ( D ) Stimulation with ox-LDL (100 µg/mL) in the presence or absence of dichloroacetate (DCA, 10 mM) for 24 h. Protein band intensities were quantified using ImageJ (version 1.48); H3K18la was normalized to H3 (15 kDa), and VCAM1 and ICAM1 to β-actin (42 kDa). Quantitative data are shown in Supplementary Fig. S14B-D ( n = 3 biological replicates). ( E ) Schematic diagram of H3K18la promotion. ( F - G ) Western blotting analysis of VCAM1 and H3K18la in HUVECs under the following conditions: ( F ) Pretreatment with or without narciclasine (Narc, 20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in combination with either NaLac (10 mM) or sodium acetate (NaAc, 10 mM) for 24 h; ( G ) Pretreatment with or without Narc (20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in the presence or absence of entinostat (MS275, 0.5 µM) for 24 h. Protein band intensities were quantified using ImageJ, with H3K18la was normalized to H3, VCAM1 to β-actin. Quantitative data are shown in Supplementary Fig. S14E and F ( n = 3 biological replicates). ( H - I ) HUVECs were pretreated with or without 20 nM Narc for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in the presence or absence of 10 mM NaLac for 24 h. ( H ) Representative images of PKH26-labeled THP-1 monocyte adhesion to endothelial cells (scale bar = 250 μm, 10× magnification). The right panel shows the quantification of adherent monocytes from 10 random fields per replicate, expressed as cells per field ( n = 3 biological replicates). ( I ) Representative images of RAW 264.7 macrophage chemotaxis toward HUVEC-conditioned medium (Scale bar = 50 μm, 20× magnification). The right panel shows the quantification of migrated cells from 5 random fields per well, expressed as cells per field ( n = 3 biological replicates). ( J ) Western blotting analysis of p-p65 (65 kDa), and p65 (65 kDa) in HUVECs pretreated with or without Narc (20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in combination with either NaLac (10 mM) or MS275 (0.5 µM) for 1 h. Protein band intensities were quantified using ImageJ, with the p-p65/p65 ratio (right panel) calculated after normalizing both p-p65 and total p65 to β-actin ( n = 3 biological replicates). ( K ) Genome browser tracks of CUT&Tag signals for H3K18la at representative target gene loci in HUVECs. The tracks display normalized signal intensity (Reads Per Kilobase per Million mapped reads, RPKM) from a single biological replicate, aligned to the GRCh38/hg38 genome build. ( L ) KEGG pathway analysis of the 1147 genes overlapping between H3K18la-bound genes and genes downregulated by Narc. The Narc-downregulated gene set was defined from RNA-seq data (FDR < 0.05, |fold change| > 1.5; n = 3 biological replicates). The underlying RNA-seq data are available under GEO accession GSE202556 . ( M ) ChIP-qPCR analyses of H3K18la enrichment at the promoters of the indicated genes in HUVECs treated with ox-LDL (100 µg/mL, 24 h) in the presence or absence of Narc (20 nM). Data were normalized to input chromatin and are presented as fold enrichment relative to the IgG control ( n = 4 biological replicates). All data were represented as mean ± SD. Statistical analysis was performed by one-way ANOVA followed by Tukey’s multiple comparisons test

    Article Snippet: Antibody against p-p65 (3031, 1:1,000) was acquired from Cell Signaling Technology, Inc. (MA).

    Techniques: Activation Assay, Inhibition, Western Blot, Transfection, Negative Control, Labeling, Chemotaxis Assay, RNA Sequencing, ChIP-qPCR, Control

    Cedrol inhibited toll-like receptor 4-mediated mitogen-activated protein kinase and nuclear factor kappa B signaling in vivo and in vitro . A-D: Phosphorylated and total protein abundance of mitogen-activated protein kinase signaling molecules [extracellular regulated protein kinase (ERK)1/2, c-Jun N-terminal kinase (JNK), p38] in colonic tissues of mice ( n = 6); E: Cellular viability was quantified with the cell counting kit-8 method ( n = 3); F-H: Proinflammatory cytokine expression in RAW264.7 macrophages across experimental groups ( n = 3); I-K: Inducible nitric oxide synthase and cyclooxygenase-2 protein expression in RAW264.7 cells across groups ( n = 3); L-P: Phosphorylated and total protein expression of ERK1/2, JNK, p38 and nuclear factor kappa B p65 in RAW264.7 macrophages ( n = 3). Data are expressed as mean ± SD. a P < 0.05. b P < 0.01. c P < 0.001. d P < 0.0001. CE: Cedrol; DSS: Dextran sulfate sodium; ERK: Extracellular regulated protein kinase; p-ERK: Phospho-extracellular regulated protein kinase; JNK: C-Jun N-terminal kinase; p-JNK: Phospho-c-Jun N-terminal kinase; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; TNF: Tumor necrosis factor; IL: Interleukin; mRNA: Messenger RNA; LPS: Lipopolysaccharide; iNOS: Inducible nitric oxide synthase; COX-2: Cyclooxygenase-2.

    Journal: World Journal of Gastroenterology

    Article Title: Cedrol ameliorates ulcerative colitis via myeloid differentiation factor 2-mediated inflammation suppression, with barrier restoration and microbiota modulation

    doi: 10.3748/wjg.v32.i2.114057

    Figure Lengend Snippet: Cedrol inhibited toll-like receptor 4-mediated mitogen-activated protein kinase and nuclear factor kappa B signaling in vivo and in vitro . A-D: Phosphorylated and total protein abundance of mitogen-activated protein kinase signaling molecules [extracellular regulated protein kinase (ERK)1/2, c-Jun N-terminal kinase (JNK), p38] in colonic tissues of mice ( n = 6); E: Cellular viability was quantified with the cell counting kit-8 method ( n = 3); F-H: Proinflammatory cytokine expression in RAW264.7 macrophages across experimental groups ( n = 3); I-K: Inducible nitric oxide synthase and cyclooxygenase-2 protein expression in RAW264.7 cells across groups ( n = 3); L-P: Phosphorylated and total protein expression of ERK1/2, JNK, p38 and nuclear factor kappa B p65 in RAW264.7 macrophages ( n = 3). Data are expressed as mean ± SD. a P < 0.05. b P < 0.01. c P < 0.001. d P < 0.0001. CE: Cedrol; DSS: Dextran sulfate sodium; ERK: Extracellular regulated protein kinase; p-ERK: Phospho-extracellular regulated protein kinase; JNK: C-Jun N-terminal kinase; p-JNK: Phospho-c-Jun N-terminal kinase; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; TNF: Tumor necrosis factor; IL: Interleukin; mRNA: Messenger RNA; LPS: Lipopolysaccharide; iNOS: Inducible nitric oxide synthase; COX-2: Cyclooxygenase-2.

    Article Snippet: After blocking in 5% skim milk, membranes were incubated overnight at 4 °C with primary antibodies targeting: Phospho-extracellular regulated protein kinase (ERK) 1/2 (Thr202/Tyr204); ERK1/2; Phospho-c-Jun N-terminal kinase (JNK) (Thr183/Tyr185); JNK; Phospho-p38 (Thr180/Tyr182); P38, phospho-nuclear factor kappa B (NF-κB) p65 (Ser536); NF-κB p65 (Cell Signaling Technology, Daners, MA, United States); Cyclooxygenase-2 (COX-2); Inducible nitric oxide synthase (iNOS); Glyceraldehyde-3-phosphate dehydrogenase (Proteintech, Wuhan, Hubei Province, China).

    Techniques: In Vivo, In Vitro, Quantitative Proteomics, Cell Counting, Expressing

    Cedrol treated dextran sulfate sodium-induced colitis by inhibiting inflammation, restoring the intestinal barrier, and rebalancing gut microbiota. TNF: Tumor necrosis factor; IL: Interleukin; DSS: Dextran sulfate sodium; LPS: Lipopolysaccharide; MD2: Myeloid differentiation factor 2; TLR4: Toll-like receptor 4; MAPK: Mitogen-activated protein kinase; ERK: Extracellular regulated protein kinase; JNK: C-Jun N-terminal kinase; NF-κB: Nuclear factor kappa B; iNOS: Inducible nitric oxide synthase; COX-2: Cyclooxygenase-2.

    Journal: World Journal of Gastroenterology

    Article Title: Cedrol ameliorates ulcerative colitis via myeloid differentiation factor 2-mediated inflammation suppression, with barrier restoration and microbiota modulation

    doi: 10.3748/wjg.v32.i2.114057

    Figure Lengend Snippet: Cedrol treated dextran sulfate sodium-induced colitis by inhibiting inflammation, restoring the intestinal barrier, and rebalancing gut microbiota. TNF: Tumor necrosis factor; IL: Interleukin; DSS: Dextran sulfate sodium; LPS: Lipopolysaccharide; MD2: Myeloid differentiation factor 2; TLR4: Toll-like receptor 4; MAPK: Mitogen-activated protein kinase; ERK: Extracellular regulated protein kinase; JNK: C-Jun N-terminal kinase; NF-κB: Nuclear factor kappa B; iNOS: Inducible nitric oxide synthase; COX-2: Cyclooxygenase-2.

    Article Snippet: After blocking in 5% skim milk, membranes were incubated overnight at 4 °C with primary antibodies targeting: Phospho-extracellular regulated protein kinase (ERK) 1/2 (Thr202/Tyr204); ERK1/2; Phospho-c-Jun N-terminal kinase (JNK) (Thr183/Tyr185); JNK; Phospho-p38 (Thr180/Tyr182); P38, phospho-nuclear factor kappa B (NF-κB) p65 (Ser536); NF-κB p65 (Cell Signaling Technology, Daners, MA, United States); Cyclooxygenase-2 (COX-2); Inducible nitric oxide synthase (iNOS); Glyceraldehyde-3-phosphate dehydrogenase (Proteintech, Wuhan, Hubei Province, China).

    Techniques: